GeneDx (WGS) - 2023 Q1 - Earnings Call Presentation

5 2023 Guidance Revenues between $205-220 million for full year 2023 v Expanded adjusted gross margin profile 2023 and beyond Use of net$95-110 million in cash in 2023 for continuing operations Inclusive of servicing obligations of the exited business activities, total cash burn in 2023 between $130-145 million, a >50% reduction year-over-year Turn to profitability in 2025 | --- | --- | |-------------------------------------------------------------------------------------------|-------| | | | | | | | One T ...